Breaking News Instant updates and real-time market news.

NG

NovaGold

$3.86

0.19 (5.18%)

, ELGX

Endologix

$1.70

-0.05 (-2.86%)

18:55
10/02/18
10/02
18:55
10/02/18
18:55

Fly Intel: After Hours Movers

UP AFTER EARNINGS: NovaGold Resources (NG) up 3.7%. ALSO HIGHER: Endologix (ELGX) up 35.5% after reporting preliminary Q3 revenue... JC Penney (JCP) up 11.5% after naming new CEO. ALSO LOWER: David's Tea (DTEA) down 20.7% after saying it had nothing to disclose to justify the 63% during market hours... Kala Pharma (KALA) down 9.5% after equity offering... Epizyme (EPZM) down 7.4% after equity offering... Nike (NKE) down 0.6% after being downgraded to Hold at HSBC.

NG

NovaGold

$3.86

0.19 (5.18%)

ELGX

Endologix

$1.70

-0.05 (-2.86%)

JCP

J.C. Penney

$1.57

-0.135 (-7.94%)

DTEA

DavidsTea

$4.18

1.62 (63.28%)

KALA

Kala Pharmaceuticals

$9.25

-0.38 (-3.95%)

EPZM

Epizyme

$9.73

-0.71 (-6.80%)

NKE

Nike

$82.79

-1.71 (-2.02%)

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 06

    Nov

  • 27

    Nov

  • 03

    Oct

  • 03

    Oct

NG NovaGold
$3.86

0.19 (5.18%)

12/19/17
RILY
12/19/17
INITIATION
Target $7
RILY
Buy
NovaGold initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Lucas Pipes started NovaGold Resources with a Buy rating and $7 price target.
ELGX Endologix
$1.70

-0.05 (-2.86%)

08/23/18
BTIG
08/23/18
NO CHANGE
Target $4
BTIG
Buy
Endologix price target lowered to $4 from $7 at BTIG
BTIG analyst Sean Lavin lowered his price target on Endologix to $4 to reflect the company's recent "drastic" reduction in FY18 revenue guidance, cuts in salesforce, and delayed clinical timelines. Lavin adds that Endologix's Q2 earnings call was also "completely negative", saying the stock is the "Cleveland Browns of MedTech World", with high potential but propensity for things to go wrong. The analyst keeps his Buy rating on Endologix on valuation, but adds that "investors will need the patience of a Browns' fan to stay involved."
08/10/18
PIPR
08/10/18
DOWNGRADE
Target $4.75
PIPR
Neutral
Endologix downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien downgraded Endologix to Neutral and lowered his price target for the shares to $4.75 from $7. The big news from the company's Q2 results is that management is meaningfully reducing revenue guidance for the year as it moves to revamp the business, O'Brien tells investors in a research note. Changes are a good idea "but the risks here are steep (lingering employee disruption, product safety concerns) compared to the rewards ," the analyst contends. He wants to move to the sidelines and see how the reorganization of the business takes shape.
03/20/18
PIPR
03/20/18
NO CHANGE
PIPR
Endologix ENCORE study a positive sign, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien was positive on Endologix's ENCORE study results for its Ovation product, and continues to believe "additional data reads and imminent approvals in the coming years should lift shares higher." O'Brien maintained an Overweight rating on shares, recommending investors with more risk tolerance or a longer time horizon accumulate shares at this point.
01/02/18
JPMS
01/02/18
DOWNGRADE
Target $5
JPMS
Underweight
Endologix downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Endologix to Underweight and cut his price target for the shares to $5 from $6. The outlook for the company continued to "deteriorate" over the course of 2017 as pipeline and regulatory challenges mounted, Weinstein tells investors in a research note. He sees an "uncertain path to profitability" and a "very long" road to recovery for Endologix.
JCP J.C. Penney
$1.57

-0.135 (-7.94%)

08/17/18
SBSH
08/17/18
NO CHANGE
Target $0.5
SBSH
Sell
J.C. Penney price target lowered to 50c from $2 at Citi
Citi analyst Paul Lejuez said that J.C. Penney " finds itself in a very difficult position" following its Q2 report given that they lack a CEO and head merchant and are struggling at a time when peers are seeing improvement in their business. While he does not see near-term liquidity issues, Lejuez said there is not that much equity value given the company's high debt load. He lowered his price target on J.C. Penney shares to 50c from $2 and keeps a Sell rating on the stock.
08/16/18
FBCO
08/16/18
NO CHANGE
Target $1
FBCO
J.C. Penney price target cut to $1 from $2 at Credit Suisse
08/16/18
BOFA
08/16/18
DOWNGRADE
BOFA
Underperform
J.C. Penney downgraded to Underperform from Neutral at BofA/Merrill
08/16/18
JPMS
08/16/18
DOWNGRADE
JPMS
Underweight
J.C. Penney downgraded to Underweight from Neutral at JPMorgan
DTEA DavidsTea
$4.18

1.62 (63.28%)

12/14/17
BMOC
12/14/17
NO CHANGE
Target $4
BMOC
Market Perform
DAVIDsTEA price target lowered to $4 from $5.50 at BMO Capital
BMO Capital analyst Kelly Bania lowered her price target on David's Tea to $4 after the company's announcement that it is seeking to explore strategic alternatives. Bania models her new price target based on the possibility that the company may seek to exit from U.S. physical store presence. The analyst also keeps her Market Perform rating on DAVID's TEA.
KALA Kala Pharmaceuticals
$9.25

-0.38 (-3.95%)

08/23/18
WELS
08/23/18
NO CHANGE
WELS
Outperform
FDA approval of Kala's Inveltys 'very positive news,' says Wells Fargo
Wells Fargo analyst David Maris says FDA approval of Kala Pharmaceuticals' Inveltys for post-operative pain inflammation and pain following ocular surgery is "very positive news." The analyst notes that Inveltys is the first and only twice- daily ocular steroid for this indication, as other products that are typically dosed at four times per day. Maris continue to believe Inveltys will be "very successful." He anticipates sales of approximately $25M in 2019, and $345M by 2025. The analyst keeps an Outperform rating on Kala amid the "sell-on-the-news reaction today."
07/23/18
HCWC
07/23/18
INITIATION
Target $35
HCWC
Buy
Kala Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Kala Pharmaceuticals with a Buy rating and $35 price target. The current valuation provides an "intriguing entry point" for investors ahead of the "risk-mitigated catalyst," the potential approval of Inveltys, Selvaraju tells investors in a research note. The analyst has "high confidence" that the drug should be approved in a "timely manner."
06/19/18
WELS
06/19/18
NO CHANGE
Target $19
WELS
Outperform
Kala Pharma's KPI-121 update suggests faster market entry, Wells Fargo says
Wells Fargo analyst David Maris kept his Outperform rating and $19 price target on Kala Pharmaceuticals, saying its announced plans to submit a new drug application for KPI-121 to the FDA in the second half of the year may expedite its market entry. The analyst adds that the most likely scenario is for the FDA to accept the company's NDA for review but ultimately consider the Stride 3 data and issue a Complete Response Letter for an additional study, which will likely lead to a class 2 resubmission and a shortened 6-month review period. Maris contends that it is also possible that the FDA "accepts Kala's NDA, finds the existing data to be sufficient, and approves KPI-121 0.25% in its first review cycle, leading to a late-2019 or early 2020 commercialization.
08/24/18
HCWC
08/24/18
NO CHANGE
Target $37
HCWC
Buy
Kala Pharmaceuticals price target raised to $37 from $35 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Kala Pharmaceuticals to $37 after the FDA approved Inveltys for the treatment of post-operative inflammation and pain following all ocular surgeries. The approval is not only a risk-mitigating milestone for the company, but also crucial validation of its MPP technology, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on Kala Pharmaceuticals.
EPZM Epizyme
$9.73

-0.71 (-6.80%)

10/02/18
10/02/18
NO CHANGE

Epizyme files to sell common stock, no amount given
Jefferies is acting as sole book-running manager for the proposed offering.
09/21/18
SBSH
09/21/18
NO CHANGE
SBSH
Buy
Citi opens 30 day catalyst watch for Epizyme
Citi analyst Robyn Karnauskas opened a 30 day catalyst watch for Epizyme in anticipation of an FDA decision on the partial hold on Tazemetostat. In the best case scenario, the analyst expects the partial hold to be lifted at the end of the 30 day period without any further delay. She notes that We note that Tazemetostat has been investigated in multiple indications, administered to 750 patients, and shown an overall positive safety profile with only a single case of secondary lymphoma. The analyst keeps a Buy rating on Epizyme.
09/24/18
LEER
09/24/18
INITIATION
Target $11
LEER
Market Perform
Epizyme initiated with a Market Perform at Leerink
Leerink analyst Andrew Berens started Epizyme with a Market Perform rating and $11 price target.
09/25/18
RHCO
09/25/18
NO CHANGE
Target $25
RHCO
Buy
Epizyme price target raised to $25 from $20 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Epizyme to $25 and kept his Buy rating, citing the FDA decision for a partial clinical hold lift on tazemetostat enrollment. The analyst notes that the company has not announced any substantial changes to the trial design or patient population, but rather will increase patient monitoring after updating its exclusion criteria for new patient enrollment. Lawson contends that the New Drug Application submission for tazemetostat in the treatment of epithelioid sarcoma expected in the first half of 2019 remains on track.
NKE Nike
$82.79

-1.71 (-2.02%)

10/02/18
HSBC
10/02/18
DOWNGRADE
Target $92
HSBC
Nike downgraded to Hold from Buy at HSBC
HSBC analyst Erwan Rambourg downgraded Nike to Hold from Buy and kept his $92 price target. The analyst notes that while the company's Q1 results were strong and the outlook "remains rock solid", the company's valuation multiple of 30-times forward earnings may weigh on the stock. Rambourg adds that the muted reaction in the stock price after better than expected Q1 suggests that the "market is pricing in a lot of positivity."
09/26/18
MSCO
09/26/18
NO CHANGE
Target $103
MSCO
Overweight
Nike margin expansion story still in early innings, says Morgan Stanley
Morgan Stanley analyst Lauren Cassel advocates buying the dip in Nike shares following the company's Q1 report as she sees its margin expansion story still being in its early innings. She continues to forecast a 17% 4-year EPS CAGR for Nike, but sees an increasing likelihood of her Bull case playing out, driven by Nike's direct-to-consumer strategy. Cassel, who raised her price target on Nike shares to $103 from $88, keeps an Overweight rating on the stock and said it remains her top pick.
09/27/18
JEFF
09/27/18
NO CHANGE
JEFF
Under Armour promos down for six straight month, says Jefferies
Jefferies analyst Randal Konik says his firm's September webscrapes illustrate that Under Armour's (UAA) percentage of product on discount is down for the sixth month in a row, while Adidas's (ADDYY) is up seven months in a row. Visits to Finish Line (FINL), Foot Locker (FL), and Under Armour websites reveal the HOVR and Curry 5 are sold out in several sizes and colors, indicating growing brand awareness, Konik tells investors in a research note. He believes Under Armour's promos being down bode well for the company's Q3 results. Further, Nike (NKE) continues to regain share from Adidas in running across the U.S., with strength in Air VaporMax, Air Max 270, and Roshe One, the analyst adds.
09/26/18
JEFF
09/26/18
NO CHANGE
Target $80
JEFF
Hold
Jefferies boosts Nike target to $80, says valuation remains elevated
Jefferies analyst Randal Konik attributes the post-earnings pullback in shares of Nike (NKE) to high expectations and a "light" Q2 revenue guidance. However, momentum in North America and the favorable direct-to-consumer shift "creates a nice set-up ahead," Konik tells investors in a research note. The analyst raised his price target for the shares to $80 from $75 but keeps a Hold rating on Nike. He views the current valuation as elevated and prefers playing the athletic space via Foot Locker (FL).

TODAY'S FREE FLY STORIES

03:00
10/17/18
10/17
03:00
10/17/18
03:00
General news
FX Action: USD-CAD has recouped to around 1.2950 »

FX Action: USD-CAD has…

02:15
10/17/18
10/17
02:15
10/17/18
02:15
General news
FX Update: The Dollar majors continue to lack direction »

FX Update: The Dollar…

01:40
10/17/18
10/17
01:40
10/17/18
01:40
General news
FX Action: USD-JPY posted a three-session high »

FX Action: USD-JPY posted…

SIBN

SI-BONE

$0.00

(0.00%)

20:54
10/16/18
10/16
20:54
10/16/18
20:54
Syndicate
SI-BONE 7.2M share IPO priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AMX

America Movil, also tag AMOV

$15.77

0.38 (2.47%)

, AMOV

America Movil, also tag AMX

$15.03

(0.00%)

20:44
10/16/18
10/16
20:44
10/16/18
20:44
Earnings
America Movil reports Q3 net income MXN18.96B vs. MXN2.52B last year »

Reports Q3 revenue…

AMX

America Movil, also tag AMOV

$15.77

0.38 (2.47%)

AMOV

America Movil, also tag AMX

$15.03

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$70.94

2.22 (3.23%)

, USB

U.S. Bancorp

$50.97

0.44 (0.87%)

20:25
10/16/18
10/16
20:25
10/16/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$70.94

2.22 (3.23%)

USB

U.S. Bancorp

$50.97

0.44 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

ADTN

Adtran

$18.15

1.08 (6.33%)

20:24
10/16/18
10/16
20:24
10/16/18
20:24
Earnings
Adtran reports Q3 adjusted EPS 21c, consensus 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

WAFD

Washington Federal

$29.75

0.45 (1.54%)

20:02
10/16/18
10/16
20:02
10/16/18
20:02
Earnings
Washington Federal reports Q4 EPS 62c, consensus 62c »

Reports Q4 NII $124.8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

UNH

UnitedHealth

$272.24

12.44 (4.79%)

19:30
10/16/18
10/16
19:30
10/16/18
19:30
Recommendations
UnitedHealth analyst commentary at Piper Jaffray »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CDAY

Ceridian

$38.44

1.38 (3.72%)

19:25
10/16/18
10/16
19:25
10/16/18
19:25
Conference/Events
Ceridian to hold a conference »

INSIGHTS 2018 will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HMC

Honda

$27.70

0.65 (2.40%)

19:07
10/16/18
10/16
19:07
10/16/18
19:07
Periodicals
Honda Aircraft sees higher light jet deliveries next year, Reuters says »

Honda Aircraft co-CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

VALE

Vale

$15.50

0.045 (0.29%)

18:59
10/16/18
10/16
18:59
10/16/18
18:59
Periodicals
Vale plans to use cash flow cautiously going forward, Reuters says »

Vale said it intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICR

Vicor Corporation

$38.35

1.42 (3.85%)

, NFLX

Netflix

$346.40

13.29 (3.99%)

18:55
10/16/18
10/16
18:55
10/16/18
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Vicor…

VICR

Vicor Corporation

$38.35

1.42 (3.85%)

NFLX

Netflix

$346.40

13.29 (3.99%)

LRCX

Lam Research

$145.33

2.72 (1.91%)

AMAT

Applied Materials

$34.76

1.33 (3.98%)

UAL

United Continental

$83.51

2.17 (2.67%)

FULT

Fulton Financial

$16.39

0.29 (1.80%)

CSX

CSX

$72.15

1.29 (1.82%)

CREE

Cree

$37.56

2.53 (7.22%)

ROKU

Roku

$63.67

1.97 (3.19%)

IBM

IBM

$145.02

3.9 (2.76%)

UFPI

Universal Forest

$34.08

1.27 (3.87%)

SONC

Sonic

$43.27

-0.03 (-0.07%)

EIGR

Eiger BioPharmaceuticals

$10.88

0.63 (6.15%)

SBH

Sally Beauty

$18.91

0.42 (2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 21

    Oct

  • 22

    Oct

  • 06

    Nov

  • 13

    Nov

  • 27

    Nov

  • 12

    Dec

  • 13

    Dec

  • 03

    Mar

NFLX

Netflix

$346.40

13.29 (3.99%)

18:38
10/16/18
10/16
18:38
10/16/18
18:38
Hot Stocks
Netflix says it has a 'long, long runway' in India »

Chief Product Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 13

    Nov

CBL

CBL & Associates

$3.52

0.085 (2.48%)

, SHLD

Sears

$0.40

0.09 (29.03%)

18:33
10/16/18
10/16
18:33
10/16/18
18:33
Hot Stocks
CBL Properties updates on redevelopment plan for Sears stores »

CBL Properties (CBL)…

CBL

CBL & Associates

$3.52

0.085 (2.48%)

SHLD

Sears

$0.40

0.09 (29.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

VZ

Verizon

$53.68

0.08 (0.15%)

18:26
10/16/18
10/16
18:26
10/16/18
18:26
Hot Stocks
Verizon says Bay, Gulf counties customers to be credited 3 months of service »

Verizon said that it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

BMO

Bank of Montreal

$80.19

0.93 (1.17%)

18:09
10/16/18
10/16
18:09
10/16/18
18:09
Periodicals
Bank of Montreal names Wolford investment banking vice chair, Reuters says »

Bank of Montreal has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

SFTBF

SoftBank

$0.00

(0.00%)

18:02
10/16/18
10/16
18:02
10/16/18
18:02
Periodicals
SoftBank COO says 'anxiously' looking at Saudi Arabia situation, Reuters says »

SoftBank COO Marcelo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

IBM

IBM

$145.02

3.9 (2.76%)

18:01
10/16/18
10/16
18:01
10/16/18
18:01
Hot Stocks
IBM sees growth in cloud overall »

Says incremental cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

CELC

Celcuity

$26.90

0.4 (1.51%)

, PBYI

Puma Biotechnology

$42.22

1.17 (2.85%)

17:57
10/16/18
10/16
17:57
10/16/18
17:57
Hot Stocks
Celcuity, Puma Biotechnology and West Cancer Center to conduct Phase 2 trial »

Celcuity (CELC) announced…

CELC

Celcuity

$26.90

0.4 (1.51%)

PBYI

Puma Biotechnology

$42.22

1.17 (2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 15

    Nov

DVN

Devon Energy

$37.08

0.98 (2.71%)

17:51
10/16/18
10/16
17:51
10/16/18
17:51
Recommendations
Devon Energy analyst commentary at MUFG »

Devon Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$36.07

1.11 (3.18%)

, VIAB

Viacom

$32.83

1.05 (3.30%)

17:51
10/16/18
10/16
17:51
10/16/18
17:51
Periodicals
Viacom launches Nickelodeon Chinese Animation Development Project, Variety says »

According to Variety,…

VIA

Viacom

$36.07

1.11 (3.18%)

VIAB

Viacom

$32.83

1.05 (3.30%)

IQ

iQIYI

$25.91

-0.19 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

BHP

BHP Billiton

$48.48

0.38 (0.79%)

17:38
10/16/18
10/16
17:38
10/16/18
17:38
Hot Stocks
BHP Billiton reports Q1 iron ore output 61.4M tons, up 10% from last year »

FY19 guidance for iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$0.00

(0.00%)

17:37
10/16/18
10/16
17:37
10/16/18
17:37
Periodicals
Uber increases junk-bond offering to $2B, Bloomberg says »

Uber has boosted the size…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$145.02

3.9 (2.76%)

17:32
10/16/18
10/16
17:32
10/16/18
17:32
Hot Stocks
IBM says growth was led by hybrid cloud, analytics and AI, digital and security »

Says remains on track…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.